Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
about
Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11HIV protease inhibitors: a review of molecular selectivity and toxicityBMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationOngoing trials in HIV protease inhibitors.Tuberculosis and HIV: a partnership against the most vulnerable.The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.Pharmacologic considerations for therapeutic success with antiretroviral agents.HIV-1 protease inhibitors.Toward antiviral strategies that resist viral escapeSafety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adultsRitonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Dual protease inhibitor therapy in the management of the HIV-1.Pharmacology and clinical experience with saquinavir.Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.Orofacial effects of antiretroviral therapies.Principles and practice of HIV-protease inhibitor pharmacoenhancement.HIV-1 protease inhibitors in development.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Adverse effects of antiretroviral therapy: focus on orofacial effects.Clinical correlates to muscle biopsy findings in HIV patients experiencing fatigue: a case series.The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with menTherapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads.Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adultsCSF penetration by antiretroviral drugs.Antiretroviral therapy: effects on orofacial health and health care.World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction.Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.Resistance to human immunodeficiency virus type 1 protease inhibitors.Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.In vitro antiviral interaction of lopinavir with other protease inhibitors.Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.A drug interaction between fusidic acid and a combination of ritonavir and saquinavir.Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
P2860
Q24534863-86944958-F303-4A9D-B678-4C0B8C7A24CEQ28082749-C623EDB9-1344-4850-9480-1E16FD5FE645Q28344472-8D53D939-DB65-485D-8F9D-F314FF78CEC0Q28344594-3ED67D01-A911-4AED-9E5F-910430A41077Q28354163-C7BA6C6D-FFD1-4550-817E-9782E1AE3C27Q30327423-96A3B8E3-1AF9-4719-97EB-73C318164A4CQ30336184-3D6DC351-478B-4CA5-8C1D-518B19BE89E5Q30692710-9AEA1469-0E54-4DA4-881C-4F0B75A7B62EQ33735400-9D7319E3-A5EA-426E-83D1-1C2E54596ACEQ33946920-4CA239DA-2065-4257-9EA7-FA1765A261C2Q33979280-C3E41DE8-C378-4D0A-A968-587ABE110B9BQ33980711-A8F4D6C1-B83C-4D12-9FEA-94CBA46B77B7Q33983571-36AA3046-0AFF-4ADE-8CD1-931AF3DD0ACDQ34181804-393EA83D-F157-451D-BFF0-61DC59AC3A4AQ34240851-F2D26DCF-4026-417C-8A73-77F2401B9FE2Q34251788-3CD26BC6-45C0-401E-89C0-2E65EE474865Q34383790-F2D73DB2-A288-4226-B250-04BDFDB56F0DQ34459378-CA6C20D0-50B6-4379-BE4A-82AED86ECE7CQ34544671-AD9695ED-CA07-4410-8FFD-8BBB90BE3223Q34720072-6DB97C7C-827B-45C8-97B0-9D0530FB89AAQ35194451-1F8E16D9-C848-4B9C-982D-B23433CF8D6FQ35207315-62F84782-0CC5-4BC2-9209-DF2944227F42Q35624701-620170B1-4832-4307-9690-75F92102FE60Q35826064-3953CF4B-5C31-4B64-AE08-D22926FDDFBAQ35878022-28E1FD42-803E-4092-96F9-7144A20A7AEEQ36094901-EF6C685C-F760-4B32-B81F-8E775E73C5C2Q36371597-3B4D6152-9F66-462E-A772-BA1882693121Q37274648-29E780EF-BA32-43C3-98CA-BBC2B484AB45Q37598597-6675FAC9-8D6F-4690-A838-134E5B22204AQ38060571-93559B4E-94AC-41DC-B77D-355A536F30A8Q38093238-C0057FDE-E3C0-4EF4-BA91-0E3359D541A0Q38646237-1EBA894F-B43D-4DA6-84C4-DE038765400EQ39511996-E6D97B00-AB80-4C81-B803-8B008253FC44Q39559316-3A766BD0-5990-4044-B6FB-75409E9D754AQ39590154-D671D38D-4EA8-4B1C-BBE2-5FA861C07A5EQ39652270-F755BCAB-C45B-483A-9AD6-CED387CDC937Q40424278-6D410663-B27A-480F-807D-397BC3ABCDE6Q42561570-078D58FD-4EDC-47F9-A5EB-789963E662D2Q43818088-7DF946E7-7798-4293-BE98-7F8DCDCC5B85Q43994824-DB7420DE-9649-4DD9-89D7-6E0AE8AD19DC
P2860
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@en
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@nl
type
label
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@en
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@nl
prefLabel
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@en
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@nl
P2093
P1433
P1476
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
@en
P2093
Cameron DW
Devanarayan V
Farthing C
Follansbee S
Granneman R
P304
P356
10.1097/00002030-199902040-00009
P407
P577
1999-02-01T00:00:00Z